FRCA Notes


Obesity

There are a smorgasbord of relevant curriculum items, including those pertaining to physiological changes and modifications to anaesthetic conduct.

In a CRQ on obesity in 2020 (46% pass rate), candidates fell down on knowing relevant basic science, drug dosing in obesity and physiological effects on the respiratory system.

Another CRQ from 2023 (73% pass rate) was overall "well answered" although specific components on obesity-related hypoventilation syndrome and TIVA dosing were not.

The topic appeared again as a CRQ in 2025 where the definition of lean body weight and pharmacological principles in obesity were poorly answered.

Resources


  • The prevalence of obesity has tripled over the past 40yrs, with greater increases in ‘developing’ compared to ‘developed’ countries
  • The UK has the sixth highest prevalence for obesity; 64% of adults are overweight or obese
  • Only five European countries have a prevalence of obesity of <20%, although the prevalence of overweight adults in these countries is still >50%
  • In the USA, 36% are obese and 89% overweight, with similar rates in Canada, Australia and New Zealand

  • BMI is commonly used as a measure of obesity
  • It is easy to calculate and can aid in planning and preparation
  • It does not describe important pathophysiological factors influencing perioperative risk such as body composition, the distribution of tissue (muscle vs. adipose) or the metabolic state
  • Class 3 obesity is now termed 'severe obesity', replacing the older term 'morbid obesity'
Category BMI (kg/m2)
Underweight <18.5
Normal weight 18.5 - 24.9
Overweight ≥25
(Pre-obese 25 - 29.9)
Obese ≥30
Class 1 obesity 30 - 34.9
Class 2 obesity 35 - 39.9
Class 3 (severe) obesity ≥40
  • Patients who are overweight or obese can be ASA 1, although class 2 obesity (ASA 2) and class 3 obesity (ASA 3) generate a higher risk

Body composition

  • Normally total body weight is comprised of 80% lean body mass (also known as fat-free mass) and 20% fat weight
  • In the overweight individual, lean body weight increases slowly relative to the increase in fat weight, so the ratio of total body weight to lean body weight increases
  • There is also an increase in total body water

Different weights used for drug dosing

  • Total body weight (TBW)

  • Ideal body weight (IBW)
    • I.e. what the patient should weigh if they had a normal ratio of lean mass to fat
    • Calculated using the Broca formula: height in centimetres minus 100 (man) or 105 (woman)

  • Lean body weight (LBW)
    • The weight of everything except body fat
    • Exceeds ideal body weight
    • Various calculations exist including the Janmahasatian formula
    • Plateaus at 100kg in men and 70kg in women

    • As IBW and LBW are calculated using height and sex, they may be the same for obese and non-obese individuals of the same height and gender
    • Giving obese patients highly lipid soluble drugs using IBW- or LBW-based dosing may result in lower plasma concentrations than anticipated
    • Equally, giving poorly lipid soluble drugs according to IBW or LBW may result in lower plasma concentrations as they do not account for the excess fat mass

  • Adjusted body weight (ABW)
    • Acknowledges that obese individuals have increased lean body mass and an increased volume of distribution for drugs
    • Uses ideal body weight + a correction factor multiplied by the excess between ideal and total body weight
    • I.e. ABW = IBW + C(TBW - IBW)
    • The use of a drug-specific correction factor reflects differing drug solubility
    • Sometimes the ABW40 is used, where the correction factor is set at 40% (a.k.a Servin's formula), for calculating ABW for the purposes of propofol infusions

Respiratory

  • Increased risk of difficult facemask ventilation and intubation

  • Lung volumes
    • Reduced FRC, which falls exponentially with BMI (approximately 5-15% for every 5kg/m2 increase)
    • Driven by cephalad displacement of the diaphragm by abdominal fat, plus thoracic and pericardial fat
    • The fall in FRC is mainly due to reduced expiratory reserve volume; residual volume is preserved and TLC only mildly reduced
    • Worse with central adiposity and when supine
    • Closing capacity may encroach on FRC, making patients prone to hypoxia due to shunt

  • Respiratory mechanics
    • Reduced lung compliance due to increased pulmonary blood volume, altered surfactant function and the weight of mediastinal fat
    • Chest wall: the pressure-volume curve shifts to the right; rather than simply reducing compliance, the extra mass imposes an inspiratory threshold load which must be overcome before inflation begins
    • Increased airway resistance (inversely related to lung volume)
    • Increased O2 consumption & CO2 production
    • Overall → increased work of breathing

  • Pleural and transpulmonary pressures
    • Pleural pressure is normally -5 to +5cmH2O; in obesity it can exceed 15cmH2O supine and reach 30cmH2O under general anaesthesia
    • Transpulmonary pressure (airway minus pleural pressure) therefore falls and may become negative at end-expiration, causing airway closure and alveolar collapse in dependent lung regions

  • Gas exchange
    • V/Q mismatch, as the collapsing dependent lung is also the best perfused
    • At BMI >40kg/m2, PaO2 may be reduced by up to 20% and the A-a gradient may be up to four times normal
    • PaCO2 is usually normal at rest (unless OHS), but there is limited capacity to meet increased ventilatory demand

  • Increased incidence/risk of:
    • Sleep disordered breathing (OSA, OHS, non-obstructive hypoxia)
    • Asthma
      • Chronic inflammatory state caused by excess adipose tissue
      • Compression of small airways due to increasing fat deposition within and around the chest & abdomen
      • Reversibility not always seen with β2 agonists
      • Weight loss improves symptoms
    • Pulmonary hypertension

Cardiovascular

  • Increased overall blood volume but lower blood volume-per-body weight i.e. 50ml/kg rather than 70ml/kg
  • Increased cardiac output
  • Reduced venous compliance and increased stressed blood volume, which help maintain venous return despite raised intrathoracic pressure
  • Raised cardiac filling pressures, particularly with coexisting diastolic dysfunction
  • Structural changes: ventricular hypertrophy, diastolic dysfunction and atrial fibrillation; visceral obesity is a major risk factor for heart failure with preserved ejection fraction
  • Increased risk of peri-operative bleeding/blood-loss
Increased risk of cardiovascular comorbidities
Hypertension (10x)
Ischaemic heart disease
Heart failure
Arrhythmias
Peripheral vascular disease
Venous thromboembolism

Gastrointestinal & metabolic

  • Increased incidence of:
    • Insulin resistance ± T2DM
    • Hiatus hernia
    • GORD
    • NASH/Fatty liver/cirrhosis
    • Hypercholesterolaemia
    • Osteoarthritis

  • Metabolic syndrome (3 or more from):
    • Central obesity
    • Hypertension
    • Impaired glucose handling or outright diabetes
    • Raised triglycerides
    • Reduced HDL cholesterol

  • Raised intra-abdominal pressure increases risk of abdominal compartment syndrome


Physiological variable Pharmacokinetic consequences
↑ Total body water ↑ VD
↑ Fat mass ↑ VD
↑ Plasma protein levels ↑ Protein binding
↑ Lean body weight ↑ Clearance (and because CO is ↑)

Absorption

  • Largely unchanged due to preserved gastrointestinal function
  • Increased cardiac output, body surface area and gut blood flow do not manifest as clinically significant
  • The exception is after bariatric surgery, which can markedly alter oral absorption (see Analgesia in severe obesity)

Distribution

  • Increased volume of distribution for both hydrophilic and lipophilic drugs due to increases in both total body water and fat mass
  • Increased protein binding due to higher levels of plasma proteins; may reduce free drug fraction

Metabolism

  • Cardiac output is higher, as is hepatic and renal blood flow, so drug delivery to organs of metabolism is increased
  • This increases clearance and metabolism of flow-limited drugs with a high extraction ratio e.g. propofol, ketamine and morphine
  • There is increased Phase II metabolism, which can reduce the clinical effectiveness of drugs cleared by this route e.g. lorazepam
  • CYP2E1 activity is increased, which increases production of the hepatotoxic paracetamol metabolite

  • Conversely metabolic pathways may be hindered by coalescing comorbidities such as fatty liver disease, chronic kidney disease, smoking or the effects of therapeutic drugs
  • Obesity in-and-of itself does not cause consistent effects on hepatic metabolism

Elimination

  • Increased cardiac output increases GFR and therefore renal clearance
  • Clearance correlates with lean body weight and therefore is increased as LBW increases in obesity
  • Methods for calculating clearance may be inaccurate and over/under-estimated

Propofol

  • Use LBW for induction boluses as this correlates well with cardiac output (onset) and plasma clearance (offset)

  • For TCI, neither the Marsh nor Schnider models are validated at extremes of weight
  • Indeed, both become inaccurate at a BMI of >37 (females) or >42 (males)
  • Overall require careful monitoring and titration to ensure adequate anaesthesia without overdosing

  • Marsh
    • Scales doses linearly with total body weight and may cause over-dosing if TBW used in obese patients
    • Does scale the central compartment according to weight
    • The algorithm does not correct body weight so one should input a calculated LBW
    • Preferable to use Servin's formula (ABW40) for propofol infusion using Marsh model
      • Benefits from a higher dose to reflect distribution of lipophilic propofol into excess fatty tissue, but may cause exaggerated cardiovascular effects

  • Schnider
    • May be more suitable as it uses age, height, weight and sex to derive compartment sizes and calculates an individualised ke0
    • Does, however, use a fixed central compartment size
    • The internal algorithm calculates LBW from TBW using the James formula, so should input the TBW

Thiopentone

  • Use IBW for induction dose due to increased VD and longer elimination half-life

Fentanyl

  • Rapid onset
  • Rapid offset in obesity due to high VD, rapid redistribution (highly lipid soluble) and increased clearance
  • However, can accumulate significantly when infused due to high lipid solubility and VD, resulting in prolonged elimination half-life and clinical effect
  • Similar effect seen in alfentanil although the prolonged effect is more related to low clearance
  • For both fentanyl and alfentanil, LBW dosing is recommended

Remifentanil

  • Dosing by TBW can produce cardiovascular depression so dosing should use LBW
  • Minto model
    • Not validated in obesity
    • Uses weight, height and age to calculate a LBW
    • Cautious titration is required

Morphine & friends

  • Obese patients are at risk of opioid-related respiratory depression due to existing OSA and accumulation of morphine + active metabolites
  • Dose by LBW with cautious titration and monitoring
  • Codeine and tramadol can pose similar risks due to idiosyncratic metabolism (codeine) and active metabolites (tramadol)

NMBA

  • Suxamethonium: dosing by TBW is appropriate as it accounts for increased pseudocholinesterase activity

  • Non-depolarising agents
    • As they are small polar molecules with a small VD, rate of clearance is largely related to metabolism
    • As metabolism correlates with LBW, this should be used for dosing
    • Use of TBW leads to prolonged action

  • Reversal agents
    • Little data exists for sugammadex and evidence supports the use of IBW, ABW40 or TBW, although SOBA guidance suggests using ABW
    • Use ABW for neostigmine

Local Anaesthetics

  • Dosing by LBW or IBW is recommended
  • However, increased plasma protein levels may reduce free fraction of LA and therefore increase dose requirements
  • Central neuraxial techniques may be unpredictable because of the effects of obesity on the epidural space

Volatile agents

  • Decreased pulmonary uptake due to reduced FRC is offset by the increase in cardiac output
  • The peripheral compartment is poorly vascularised somewhat mitigating its increased size
  • More lipid-soluble agents may accumulate for prolonged procedures, but for short procedures there is little difference
  • Pharmacokinetics of sevoflurane and desflurane unaltered

  • The leading causes of perioperative morbidity and mortality in severe obesity are VTE, lower respiratory tract infection and respiratory failure
  • Good analgesia facilitates early mobilisation, oral intake and discharge, reducing all of these

  • Sleep-disordered breathing is the most important comorbidity for pain management
    • Patients with untreated or undiagnosed moderate-to-severe OSA are at greatest risk of postoperative respiratory adverse events, especially with opioid-centric analgesia
    • Opioids impair the arousal response, worsen airway obstruction and reduce respiratory rate and effort in a dose-dependent manner
    • OSA may also increase pain perception and opioid sensitivity
    • The first 24h after a long-acting opioid dose appears to be the most dangerous period

  • Other relevant comorbidities: hepatic and renal dysfunction, gastroparesis, chronic pain (osteoarthritis, back pain, fibromyalgia) and psychosocial factors

Principles

  • Aim for opioid-sparing rather than opioid-free analgesia; opioid-free anaesthesia may be less effective than hoped and its cardiovascular depressant effects may outweigh the benefits
  • Tailor the regimen to the surgery, the patient's comorbidities and the character of their pain
  • Regular paracetamol and NSAIDs unless contraindicated
  • Prioritise regional and neuraxial techniques where appropriate
  • Add antihyperalgesics (ketamine, lidocaine or dexmedetomidine) in high-risk patients, hyperalgesia or neuropathic pain
  • A naloxone rescue protocol should be readily available

Paracetamol

  • Pre-emptive and regular IV dosing is recommended where possible
  • Plasma concentrations are lower in obesity, but the standard 1g (4g/day) dose should not be exceeded because increased CYP2E1 activity produces more hepatotoxic metabolite
  • Reduce the dose if there are risk factors for hepatotoxicity e.g. NASH

NSAIDs

  • Reduce opioid consumption and recovery room stay after bariatric surgery without increasing surgical complications
  • After previous bariatric surgery, short-term use is acceptable but prolonged use is contraindicated due to risk of marginal (anastomotic) ulceration

Dexmedetomidine

  • α2-agonist; only licensed for ICU sedation in the UK but widely used intra-operatively in bariatric practice
  • In its clinical range it does not depress airway tone or respiratory drive, so is particularly useful in OSA
  • Excessive doses cause prolonged sedation, hypotension and bradycardia, hence IBW dosing
  • May prolong the duration of regional blocks

IV lidocaine

  • Anti-inflammatory, antihyperalgesic and opioid-sparing
  • Dose by LBW given the risk of LA toxicity
  • Account for any LA used in blocks or wound infiltration; consider delaying the infusion for 4-8h after a regional block
  • Reduce or avoid in hepatic dysfunction

Ketamine

  • The preferred parenteral non-opioid analgesic in severe obesity as it is opioid-sparing with minimal respiratory depression
  • Infusions useful after painful surgery (spine, trauma, open abdominal) or where hyperalgesia is present
  • Rescue analgesia in recovery: 2-5mg every 5-10min (maximum 20mg/h)
  • Can be added to an opioid PCA
  • Dose by IBW to avoid psychotomimetic effects

Gabapentinoids

  • Associated with respiratory depression, particularly in the elderly, those with OSA and those receiving opioids
  • Meta-analysis showed no clinically significant analgesic benefit, no prevention of chronic post-surgical pain and more adverse events
  • Do not start perioperatively in severe obesity, especially with known or suspected SDB
  • Continue in those already taking them, at a reduced dose if opioids are also being given, with extended monitoring

Other adjuncts

  • Magnesium: NMDA and calcium channel blockade, also reduces PONV and shivering; evidence for analgesic benefit is low quality
  • Dexamethasone: analgesic at doses >0.1mg/kg and recommended by bariatric ERAS guidelines; causes dose-dependent hyperglycaemia without clinically significant consequences, so is safe in diabetics

Regional & neuraxial techniques

  • Technically more difficult, but ultrasound-guided block success remains high (~95%)
  • Optimise patient positioning and operator ergonomics; a curvilinear probe and longer needles may be needed for deep targets e.g. TAP blocks
  • Neuraxial: greater skin-to-epidural depth and impalpable landmarks; ultrasound reduces attempts, time and failure

  • Intrathecal morphine
    • Historically avoided in severe obesity/SDB due to concern for delayed respiratory depression
    • At doses <0.3mg, risk of respiratory depression is lower than with IV opioids; 0.1mg in OSA did not increase pulmonary complications or apnoea severity
    • Use where it is part of the standard protocol for that surgery, with respiratory monitoring for at least 24h

Opioids

  • Acceptable with appropriate precautions; dose by LBW (AAGBI/SOBA)
  • Do not increase dose or frequency unless there is chronic pain or opioid tolerance
  • Use short-acting (fentanyl) or intermediate-acting (hydromorphone) opioids rather than long-acting or modified-release preparations
  • IV PCA is reasonable, always alongside regular simple analgesia
  • Avoid background opioid infusions, which are strongly associated with respiratory depression

Specific patient groups

  • Elderly
    • SDB increases with age and contributes to delirium risk
    • Balance analgesia against sedation and polypharmacy; regional techniques are particularly useful
    • Avoid gabapentinoids, tramadol, pethidine and high-dose or modified-release opioids
    • Review home medications for withdrawal risk (e.g. benzodiazepines) and interactions
    • NSAIDs at the lowest dose for the shortest duration

  • Day-case
    • Severe obesity alone does not predict prolonged recovery or readmission
    • Patients with diagnosed and well-controlled OSA can safely undergo day-case surgery; consider whether the procedure will be very painful and whether it can be managed without opioids
    • Use LA infiltration or blocks; deliberately prescribe regular paracetamol and NSAIDs; agree safe discharge opioid quantities with the surgeon

  • Chronic pain and opioid tolerance
    • Not immune to respiratory depression; chronic opioid use is associated with central apnoea in a dose-dependent manner
    • Pre-operatively: screen for SDB, involve the pain team, calculate daily oral morphine equivalents, identify substance use disorders and counsel on expectations
    • Keep in a monitored setting if opioid doses are increased or sedating drugs added; opioid rotation should be supervised by the acute pain service

  • Previous bariatric surgery
    • Oral drug absorption changes acutely and long-term
    • Methadone levels rise after sleeve gastrectomy, buprenorphine levels fluctuate and oral morphine is absorbed faster after Roux-en-Y gastric bypass

  • The health risk from obesity is not uniform, with increased risk of obesity-associated health conditions in Black African-Caribbean, Asian and elderly populations

BMI

  • Obesity does not necessarily increase the risk of perioperative morbidity and mortality
    • Class 3 obesity is associated with increased post-operative morbidity and mortality
    • Conversely, class 1 & 2 patients often have a lower incidence of complications and mortality than normal weight patients, a finding across a range of surgeries
    • Underweight patients carry the highest risk of mortality among the different categories of BMI

  • This may be due to unrecognised differences between BMI groups rather than a beneficial effect from adipose tissue per se

Age

  • Increasing age is associated with reduced functional reserve, and carries an increased risk of post-operative morbidity and mortality
  • In obesity, this association is not as concrete
    • In Class 3 obese patients undergoing PLIF, age >65yrs was independently associated with increased risk of post-operative complications
    • Overall mortality was increased 3x in patients undergoing bariatric surgery aged >55yrs compared to those <55yrs

Distribution of fat

  • Central (abdominal/visceral) obesity is defined as:
    • Waist circumference >102cm (men) or >88cm (women)
    • (Or >90cm and >80cm in Asian men and women)

  • Adipose tissue distribution can be defined by CT and MRI
  • However simple measurement of waist circumference can identify those with greater perioperative risk
  • The distribution of fat predicts mortality more accurately than BMI

  • Central obesity has greater associated risks of:
    • Difficult airway/ventilation management
    • Cardiovascular disease
    • Metabolic syndrome
    • Overall peri-operative risk

Presence of comorbidities

  • The degree to which comorbidities increase peri-operative risk for obese patients is not clear
  • OSA is associated with difficult airway management, unplanned re-intubation and post-operative cardiopulmonary complications

  • Metabolic syndrome comprises a cluster of conditions and contributes majorly to perioperative morbidity and mortality, with increased risk of:
    • Developing cardiovascular disease
    • Developing T2DM
    • Post-operative cardiac complications (2-3x)
    • Post-operative pulmonary complications (1.5-2.5x)
    • Stroke
    • Sepsis

Functional capacity

  • The ability to achieve >4 METs indicates a lower risk
  • However, obese patients may not exert themselves to this degree and this does not alone define an unfit patient

  • Sarcopenic obesity is characterised by reduced muscle mass and functionality in the presence of obesity
    • There are trends towards adverse outcomes, particularly with age
    • Varying diagnostic criteria result in the exact risk being unclear
    • The presence of sarcopenic obesity is suggested by:
      1. Poor grip strength
      2. History of immobility
      3. Slow gait

Atelectasis in obesity

  • Atelectasis occurs in up to 90% of patients under general anaesthesia and promotes other postoperative pulmonary complications (PPCs) such as pneumonia
  • Risk is markedly greater in obesity due to raised pleural pressure, reduced alveolar pressure and impaired surfactant function
  • After induction and neuromuscular blockade, abdominal and thoracic fat push the diaphragm cephalad; dependent regions develop negative transpulmonary pressure and collapse
  • End-expiratory lung volume can fall by up to 50% in class 3 obesity, to levels comparable with severe ARDS
  • Further worsened by pneumoperitoneum, Trendelenburg positioning and high FiO2 (absorption atelectasis); improved by a more upright position
  • Collapse and reduced lung volume persist after extubation, causing post-operative desaturation

Role of PEEP and recruitment

  • PEEP raises transpulmonary pressure to counteract the inward forces on the lung, maintaining end-expiratory lung volume and improving V/Q matching, compliance and oxygenation
  • Due to hysteresis, the pressure needed to re-open collapsed alveoli is much higher than the pressure at which they close
    • An alveolar recruitment manoeuvre (ARM) is therefore needed first; airway pressures of 40-50cmH2O may be required in obesity
    • PEEP must then be kept above the closing pressure to prevent de-recruitment
  • Adequate PEEP lowers driving pressure, a surrogate of lung strain that is closely associated with outcome
  • Pleural pressure is not uniform: it is highest in dependent lung, so PEEP high enough to open dorsal lung may overdistend ventral lung
Advantages of PEEP in obesity Disadvantages of PEEP in obesity
Reduced atelectasis and maintained lung volume Overdistension of non-dependent lung if excessive
Improved compliance and lower driving pressure ↑ PVR and RV afterload if overdistended
Improved V/Q matching and oxygenation ↓ Venous return, especially with hypovolaemia or cardiovascular disease
Reduced hypoxic pulmonary vasoconstriction → ↓ RV afterload Hypotension and bradycardia with accompanying ARMs
Prevents airway closure and cyclical opening Physiological benefits lost within hours of extubation

Evidence

  • The PROBESE trial (JAMA, 2019) compared PEEP 12cmH2O with ARMs vs. PEEP 4cmH2O in obese surgical patients
    • High PEEP improved respiratory mechanics and gas exchange
    • No reduction in PPCs, and more intra-operative hypotension in the high PEEP/ARM group
  • 12cmH2O may have been too low; studies personalising PEEP in class 3 obesity typically find optimal levels of 15-25cmH2O, rising with BMI
  • In practice, over 75% of obese patients receive PEEP ≤5cmH2O
  • Personalised PEEP improves intra-operative physiology, but improvement in patient-centred outcomes has not yet been shown

Cardiovascular effects of PEEP

  • The heart and great vessels are affected by pleural pressure, whereas the pulmonary circulation is affected by transpulmonary pressure
  • In obesity, the already high pleural pressure (25-30cmH2O under GA) buffers the circulation from the effects of PEEP; reduced venous compliance and increased stressed volume help maintain venous return
  • Studies of personalised PEEP in obesity show preserved cardiac output and no increase in vasopressor requirement, even at PEEP >20cmH2O
  • Recruitment manoeuvres, rather than PEEP itself, appear to be the main cause of hypotension and bradycardia; take particular care with hypovolaemia, shock or cardiovascular disease
  • PEEP reduces LV transmural pressure and therefore LV afterload
  • At emergence, atelectasis, increased work of breathing and upper airway obstruction can generate large negative intrathoracic pressures, increasing LV afterload and venous return; this risks pulmonary oedema and extubation failure

A practical approach to personalised PEEP

  • Start lung protective ventilation: VT 6-8ml/kg predicted body weight, PEEP 10cmH2O
  • Suspect significant atelectasis if:
    • Driving pressure >14cmH2O
    • Progressively falling static compliance
    • Hypoxaemia or rising FiO2 requirement
  • Recruitment manoeuvre: confirm haemodynamic stability, then deliver 3-6 breaths at a plateau pressure of 40-50cmH2O
  • Decremental PEEP trial (volume-controlled ventilation):
    • Start at 20-25cmH2O, adjusted for BMI and surgical conditions
    • Reduce in 2cmH2O steps every 10 breaths whilst monitoring static compliance
    • Select the lowest PEEP that gives the highest compliance
  • Reassess as conditions change (insufflation, positioning); if haemodynamic compromise occurs, avoid further ARMs and consider lowering PEEP

Perioperative management of the obese patient


History and examination

  • Document weight and BMI
  • Elucidate functional status

  • Identify important factors such as:
    • Whether fat distribution is central or peripheral
    • The presence of metabolic syndrome
    • SpO2 <95% on room air
    • Presence of other comorbidities that require investigation and optimisation

Investigations

  • These will be guided by the individual's comorbidities and the surgery planned

  • Respiratory
    • Resting SpO2 on air
    • History: dyspnoea, wheeze
    • Screening e.g. STOP-BANG
    • FBC to check for polycythaemia
    • ABG to check for hypercapnoea and/or raised bicarbonate
    • Spirometry

  • Cardiovascular
    • Resting HR, NIBP
    • History: exertional chest pain, palpitations, overt features of heart failure, syncope
    • 12-lead ECG
    • Exercise capacity ± CPET
    • TTE
    • Cardiology input

  • Metabolic
    • Serum glucose
    • HbA1c
    • LFTs
    • Actively seek components of metabolic syndrome
    • Diabetes/endocrine input

Risk assessment

  • Risk prediction can be facilitated with the Obesity Surgery Mortality Risk Score (OS-MRS); it is only validated in bariatric surgery but may be used in non-bariatric surgery
  • The score can be used to plan the need for postoperative care; a score of 4-5 indicates a high-risk patient and should prompt consideration of post-operative HDU admission
Risk Factor Score
BMI >50kg/m2 1
Male 1
Hypertension 1
Age >45yrs 1
Any risk factor for PE:
OSA/OHS
Previous VTE
Right heart failure
Pulmonary hypertension
IVC filter inserted pre-operatively
Max 1

Considerations for day surgery

  • Obesity in-and-of itself is not a contraindication to day surgery, and severe obesity alone does not predict prolonged recovery or readmission
  • Other than a requirement for long-acting post-operative opioids, there are no significant anaesthetic or surgical factors which will otherwise contraindicate the obese patient having day surgery
  • Diagnosed and well-controlled OSA is not a barrier; consider whether the procedure will be very painful and whether it can be managed with non-opioid techniques
  • Several patient factors may make day surgery inappropriate, such as:
    • Poor functional capacity
    • Unstable respiratory or cardiac disease
    • Metabolic syndrome
    • OS-MRS of 4 or 5
    • Previous VTE

Planning analgesia

  • Identify comorbidities which affect analgesia (SDB, hepatic/renal dysfunction, chronic pain, chronic opioid use, psychosocial factors) and other predictors of poorly controlled pain
  • Refer those at risk of persistent post-surgical pain to specialist pain services
  • Chronic pain patients: involve the pain team, calculate daily oral morphine equivalents and screen for SDB early

  • The 'evaluate, educate, engage, empower' approach
    • Evaluate: comorbidities and pain risk as above
    • Educate: set realistic expectations and reduce anxiety and catastrophising
    • Engage: increase activity and prehabilitation before surgery
    • Empower: patients record their own baseline function (e.g. 6-minute walk test, peak expiratory flow) and work towards a 'return to baseline' after surgery

Optimisation & planning

  • Consider CPAP/NIV for patients with OSA/OHS; positive airway pressure therapy in OSA is associated with a 28% reduction in post-operative respiratory complications and 56% reduction in unplanned ICU admission
  • Medical management of cardiovascular and metabolic comorbidities
  • Weight loss where possible
  • Senior anaesthetist and senior surgeon on the list
  • Allow extra list time for both anaesthetic and surgical components
  • Plan for HDU/ICU post-operatively if appropriate; diabetes, respiratory disease and open abdominal surgery are associated with higher risk of unanticipated ICU admission

General equipment

  • Suitable gowns and theatre-wear of appropriate size

  • Appropriate transfer equipment should be available:
    • Patient should maintain their own mobility as much as possible
    • Equipment such as chairs, trolleys and beds should be safe to use at patient’s weight
    • May require use of hover mattresses or similar devices
    • Adequate staff members present to facilitate safe transfer

  • Oxford HELP pillow or ramping device
  • Large IPCs or TEDS (10x increased risk DVT)
  • Sufficient staff to move the patient
  • Once on the operating table, require:
    • Extra-wide extensions or arm gutters
    • Gel pads to protect pressure points as prolonged pressure can cause ischaemia and rhabdomyolysis (classically gluteal ischaemia)

Anaesthetic equipment

  • Large NIBP cuff; may need to use forearm for measurement
  • Do not routinely require intra-arterial BP monitoring
  • Predict difficult intubation therefore VL and associated difficult airway kit
  • Long spinal/epidural and regional needles, and a curvilinear ultrasound probe, if RA planned
  • Ultrasound machine in case of difficult vascular access
  • Ventilator capable of delivering suitable driving pressure and PEEP
  • Neuromuscular monitoring as higher potential for incomplete reversal of NMBA

Induction & airway

  • Obesity is associated with a higher risk of developing airway problems under anaesthesia, with NAP4 demonstrating:
    • 2x rate of adverse events (esp. with SAD)
    • Higher failure of rescue techniques

  • Routine airway assessment should be performed, with particular emphasis on identifying:
    • Mallampati III (predicts difficult facemask ventilation and intubation)
    • Neck circumference >42cm (one of the best predictors of difficult intubation)
    • BMI >50 kg/m2 (independent predictor of both difficult intubation and facemask ventilation)
    • The presence of a beard
    • Symptoms of gastro-oesophageal reflux disease

  • Induction
    • In theatre to mitigate unnecessary transfer risk and allow greater space and access to assistance
    • Induce in ramped position as maintains FRC, reduces dyspnoea and facilitates BVM/laryngoscopy

  • Airway choices
    • Likely to require intubation and therefore need appropriate equipment to facilitate this, including video laryngoscopy and adjuncts
    • A SAD may be appropriate; a 2nd generation device should be used and should definitely be used with caution if BMI >40kg/m2
    • An airway plan should be vocalised and DAS guidelines followed
    • Routine fibreoptic intubation is not recommended
    • FONA may be more difficult if required and have higher rate of failure/complications; may be appropriate in high risk cases to identify the depth of the cricothyroid membrane, vascular tissue, and mark relevant landmarks to improve the chance of success

  • Obesity is associated with an increased incidence of known risk factors for aspiration
    • However, obesity alone does not increase risk of reflux and pulmonary aspiration
    • In the absence of other risk factors, routine performance of RSI is not required

  • There is a higher risk of hypercapnoea and hypoxia, as increased body tissue mass and work of breathing leads to greater oxygen consumption and CO2 production
  • FRC is reduced to closing capacity and causes atelectasis and hypoxia, due to:
    • Excess adipose tissue, which reduces lung compliance and raises pleural pressure
    • Lying supine
    • General anaesthesia and neuromuscular blockade
    • Effect of pneumoperitoneum

Maintenance of anaesthesia

  • NAP5 revealed an increased incidence of awareness in obese patients shortly after induction of anaesthesia, due to rapid redistribution of anaesthetic agents
  • In order to reduce occurrence, anaesthetists should ensure:
    • Adequate dosing of IV agent
    • Prompt delivery of maintenance anaesthetic agent
    • Further bolus(es) of anaesthetic agent before airway manipulation or protracted airway manoeuvres
    • Using processed EEG-based depth of anaesthesia monitoring to reduce risk of awareness

  • TIVA with propofol offers a number of potential advantages over volatile anaesthesia for the obese patient:
    • Reduced incidence of laryngospasm
    • Maintained anaesthesia during protracted airway manipulation
    • Rapid offset with ‘clear-headed’ emergence
    • Reliable clearance of hypnotic agents
    • Reduced PONV

  • Using volatile agents with a rapid offset of action (low blood:gas partition coefficient) e.g. desflurane/sevoflurane should limit adipose absorption and reduce risk of re-sedation at emergence

Ventilation

  • Obesity is an independent risk factor for developing postoperative pulmonary complications
  • Current recommendations for ventilation include:
    • Lung protective volumes (6-8ml/kg predicted body weight)
    • Plateau pressure <30cmH2O outside of recruitment manoeuvres
    • Initial PEEP of around 10cmH2O, then individualised; class 3 obesity often requires >15cmH2O
  • Recruitment manoeuvres and a decremental PEEP trial where atelectasis is suspected (see Ventilation and PEEP under general anaesthesia)
  • Re-titrate PEEP with changes in positioning and pneumoperitoneum, e.g. Trendelenburg position in lower abdominal surgery with laparoscopy

Analgesia

  • Opioid-sparing multimodal approach: regular paracetamol and NSAIDs, regional or neuraxial techniques and surgical LA infiltration where possible
  • Consider dexmedetomidine, ketamine or lidocaine infusions, dosed by the appropriate scalar (see Analgesia in severe obesity)
  • Single-dose dexamethasone as part of PONV prophylaxis also provides analgesia

Reversal of NMBA and emergence

  • The hazards of airway/respiratory problems during emergence are greater in the obese population
  • To mitigate for this ensure:
    • Ventilate with FiO2 1.0 until FEO2 >0.9
    • Sit upright or at least ramped
    • Full reversal of NMBA with appropriate doses of sugammadex or neostigmine
    • Only extubate once fully awake

Effect of previous bariatric surgery

  • Patients may have undergone previous bariatric surgery
  • This may influence conduct of anaesthesia

  • Adjustable gastric banding
    • High risk of aspiration even with prolonged fasting times
    • Antacid premedication + RSI technique
    • Avoid routine NGT insertion as risk of band displacement or perforation
    • Do not deflate band without discussing with a bariatric surgeon

  • Sleeve gastrectomy
    • Routinely intubate even if no other risk factors for aspiration
    • High risk of gastric reflux even in the absence of symptoms

  • Malabsorptive surgery
    • Small bowel shortening can affect oral bioavailability of drugs, in particular post-operative analgesia

  • Avoid prolonged NSAID use after any bariatric surgery due to the risk of anastomotic ulceration

  • Recover in upright position
  • Consider HDU care for those with existing hypoventilatory issues, need for NIV or other need for closer monitoring
  • Continue home CPAP/NIV; the intra-operative benefits of PEEP are lost within hours of extubation as atelectasis recurs

  • Multi-modal opioid-sparing analgesic strategy
    • Use of intra-operative IV agents as part of a multi-modal approach reduces opioid usage, PONV, POPC, PACU length of stay and hospital LOS (BJA, 2024)
    • Regular paracetamol and NSAIDs unless contraindicated
    • Small IV ketamine boluses as rescue analgesia, or low-dose infusions for hyperalgesia or escalating opioid requirements
    • Aim to avoid opioids where possible to limit respiratory depression
    • If using, use short-acting opioids e.g. fentanyl; PCA without a background infusion
    • Do not start gabapentinoids

  • Monitoring
    • If IV opioids are required, continuous saturations monitoring should be in situ
    • Monitor for at least 24h after intrathecal morphine
    • The first 24h after long-acting opioids carries the highest risk of respiratory depression
    • Naloxone readily available

  • Multi-modal anti-emesis as standard

  • Robust venous thromboprophylaxis
    • Early mobilisation
    • Chemical prophylaxis based on total body weight dosing

  • After discharge
    • Early follow-up to ensure pain is well-controlled and safely managed
    • Discharge opioid quantities agreed with the surgical team
    • Patients track their recovery against their own pre-operative baseline